Welcome to the international HTA database

Showing [21846 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ribociclib (breast cancer; combination with fulvestrant) - Benefit assessment according to §35a Social Code Book V]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[CT or MRT diagnostics for suspected chronic coronary heart disease: an evidence mapping]
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Bedaquiline (new therapeutic indication: multi-drug-resistant pulmonary tuberculosis, 12 to < 18 years)]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Urinary proteome analysis for detection of diabetic nephropathy in patients with diabetes mellitus and arterial hypertension. Update of Commission D13-01. - Rapid Report]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tisagenlecleucel (B-cell acute lymphoblastic leukaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2020	Malaysian Health Technology Assessment (MaHTAS)	Influenza vaccination for the elderly and economic evaluation
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tisagenlecleucel (diffuse large B-cell lymphoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2020	Swiss Federal Office of Public Health (FOPH)	Olmesartan mono- and combination therapy in patients with essential hypertension
2020	Malaysian Health Technology Assessment (MaHTAS)	Intravenous iron for iron deficiency anaemia
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Romosozumab (osteoporosis) - Benefit assessment according to §35a Social Code Book V]
2020	Swiss Federal Office of Public Health (FOPH)	Treatment of non-erosive gastroesophageal reflux disease patients with proton pump inhibitor therapy
2020	Malaysian Health Technology Assessment (MaHTAS)	Programmatic management of latent tuberculosis infection
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Fidaxomicin (clostridioides difficile infection) - Benefit assessment according to §35a Social Code Book V]
2020	Malaysian Health Technology Assessment (MaHTAS)	Automatic guided vehicles (AGVs) for transportation of food and materials in hospitals
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Abemaciclib (breast cancer; combination with fulvestrant) - Benefit assessment according to §35a Social Code Book V]
2020	NIHR Health Technology Assessment programme	Seizure first aid training for people with epilepsy attending emergency departments and their significant others: the SAFE intervention and feasibility RCT
2020	Malaysian Health Technology Assessment (MaHTAS)	Digital dental impression
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Riociguat (CTEPH) - Benefit assessment according to §35a Social Code Book V]
2020	Malaysian Health Technology Assessment (MaHTAS)	Biocompatible peritoneal dialysis (PD) solution
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Riociguat (PAH) - Benefit assessment according to §35a Social Code Book V]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Brolucizumab (neovascular age-related macular degeneration) - Benefit assessment according to §35a Social Code Book V]
2020	Swiss Federal Office of Public Health (FOPH)	Iron therapy for iron deficiency without anemia
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cobicistat (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Avelumab (metastatic Merkel cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ceftolozane/tazobactam (hospital-acquired pneumonia) - Benefit assessment according to §35a Social Code Book V]
2020	Health Technology Wales (HTW)	Autologous haematopoietic stem cell transplantation for previously treated, relapsing-remitting multiple sclerosis
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ceftolozane/tazobactam (complicated intra-abdominal infections) - Benefit assessment according to §35a Social Code Book V]
2020	The Regional Health Technology Assessment Centre (HTA-centrum)	Does headgear type used by the operating room staff affect postoperative surgical site infection rate?
2020	Health Technology Wales (HTW)	Pre-operative cardiopulmonary exercise testing for people in whom major abdominal surgery is planned
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ceftolozane/tazobactam (complicated urinary tract infections) - Benefit assessment according to §35a Social Code Book V]
2020	The Regional Health Technology Assessment Centre (HTA-centrum)	Efficacy of transcutaneous vagus nerve stimulation as treatment for patients with depression
2020	Health Technology Wales (HTW)	Rapid antigen detecting tests for diagnosing group A streptococcal infections in the community pharmacy setting
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ceftolozane/tazobactam (acute pyelonephritis) - Benefit assessment according to §35a Social Code Book V]
2020	NIHR Health Technology Assessment programme	Understanding the health-care experiences of people with sickle cell disorder transitioning from paediatric to adult services: This Sickle Cell Life, a longitudinal qualitative study
2020	Health Technology Wales (HTW)	Transcatheter aortic valve implantation (TAVI) for the treatment of patients with severe symptomatic aortic stenosis who are at intermediate surgical risk
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2020	Health Technology Wales (HTW)	Point of care haemolysis detection in blood samples that may be deemed unfit for laboratory analysis
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Trifluridine/tipiracil (colorectal cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Use of statutory health insurance (BARMER) data in IQWiG's dossier assessment procedure]
2020	The Regional Health Technology Assessment Centre (HTA-centrum)	Is there an association between the proportion of registered nurses (skill-mix) in the hospital health care team, and patient mortality or risk for falls or pressure ulcers?
2020	NIHR Health Technology Assessment programme	Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis
2020	Malaysian Health Technology Assessment (MaHTAS)	Acupuncture for headache, refractory neuralgia, Bell’s palsy, post-stroke, Guillain barre and transverse myelitis
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Givosiran (acute hepatic porphyria) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Implantable automatic defibrillator for primary prevention of sudden cardiac death in Spain: efficacy, safety, and efficiency]
2020	The Regional Health Technology Assessment Centre (HTA-centrum)	Safety and effectiveness of outpatient compared with inpatient induction of labour in singleton uncomplicated pregnancies
2020	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Effectiveness and safety of the left ventricular assist device (LVAD) as destination therapy in paediatric patients]
2020	Malaysian Health Technology Assessment (MaHTAS)	Laser fluorescence to detect tooth decay within the tooth structure
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Insulin glargine/lixisenatide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2020	The Regional Health Technology Assessment Centre (HTA-centrum)	Magnetic resonance image-guided radiotherapy in patients with cancer in thorax, abdomen, pelvis or head and neck
2020	Andalusian Health Technology Assessment Area (AETSA)	[Tumor field therapy in the treatment of glioblastoma. Update]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Venetoclax (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V]
2020	The Regional Health Technology Assessment Centre (HTA-centrum)	Anti-inflammatory, antibiotic and immunomodulatory treatment in children with symptoms corresponding to the research condition PANS (Pediatric Acute-onset Neuropsychiatric Syndrome)
2020	NIHR Health Technology Assessment programme	An app-, web- and social support-based weight loss intervention for adults with obesity: the HelpMeDoIt! feasibility RCT
2020	NIHR Health Services and Delivery Research programme	The effects of interoperable information technology networks on patient safety: a realist synthesis
2020	Andalusian Health Technology Assessment Area (AETSA)	[Care model for women with endometriosis. Systematic review of clinical practice guidelines]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Daratumumab (newly diagnosed multiple myeloma, stem cell transplant unsuitable) - Addendum to Commission A20-14]
2020	The Regional Health Technology Assessment Centre (HTA-centrum)	Effectiveness of laminar versus turbulent airflow in operating theaters, with regard to risk for postoperative surgical infections
2020	European Network for Health Technology Assessment (EUnetHTA)	Rolling Collaborative Review COVID-19 - Lopinavir + Ritonavir
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Siponimod (multiple sclerosis) - Addendum to Commission A20-10]
2020	The Regional Health Technology Assessment Centre (HTA-centrum)	Update: Chlorhexidine wash prior to clean surgical procedures
2020	NIHR Health Services and Delivery Research programme	Social norms interventions to change clinical behaviour in health workers: a systematic review and meta-analysis
2020	Belgian Health Care Knowledge Centre (KCE)	Polyvalent immunoglobulins – Part 2: use in Belgium
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Daratumumab (newly diagnosed multiple myeloma, stem cell transplant suitable) - Addendum to Commission A20-15]
2020	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Efficacy and safety of active spiritual healing]
2020	The Regional Health Technology Assessment Centre (HTA-centrum)	Nature-based rehabilitation for patients with longstanding stress-related disorders – an updated report
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Brigatinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2020	The Regional Health Technology Assessment Centre (HTA-centrum)	Induction of labour at 41 or 42 weeks of gestation
2020	NIHR Health Technology Assessment programme	Gabapentin to reduce pain in women aged between 18 and 50 years with chronic pelvic pain: the GaPP2 RCT
2020	Malaysian Health Technology Assessment (MaHTAS)	Prophylactic anticoagulation in ambulatory cancer patients
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ribociclib (breast cancer, combination with an aromatase inhibitor) - Addendum to commission A20-21]
2020	NIHR Health Technology Assessment programme	Ursodeoxycholic acid to reduce adverse perinatal outcomes for intrahepatic cholestasis of pregnancy: the PITCHES RCT
2020	Norwegian Institute of Public Health (NIPH)	[Intermittent pneumatic compression for preventing deep vein thrombosis in acute stroke, a health technology assessment]
2020	Malaysian Health Technology Assessment (MaHTAS)	Antifibrotic for treatment of idiopathic pulmonary fibrosis
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Atezolizumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ribociclib (breast cancer, combination with fulvestrant) - Addendum to commission A20-22]
2020	Norwegian Institute of Public Health (NIPH)	[Effectiveness of microwave thermotherapy (TUMT) compared to transurethral resection of the prostate (TURP) for benign prostatic hyperplasia]
2020	Malaysian Health Technology Assessment (MaHTAS)	Needleless Vacutainer system for blood collection
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Darolutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2020	NIHR Health Services and Delivery Research programme	Variations in the organisation of Early Pregnancy Assessment Units (EPAUs) in the UK and their effects on clinical, service and patient-centred outcomes (VESPA)
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Apalutamide (prostate cancer) - Addendum to Commission A20-20]
2020	NIHR Health Technology Assessment programme	Rapid antigen detection and molecular tests for group A streptococcal infections for acute sore throat: systematic reviews and economic evaluation
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Apremilast (Behçet’s disease) - Benefit assessment according to §35a Social Code Book V]
2020	Scottish Health Technologies Group (SHTG)	The SARUS (safer - airway - resuscitation) - CPR hood to protect first responders from biohazards
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Solriamfetol (narcolepsy) - Benefit assessment according to §35a Social Code Book V]
2020	Scottish Health Technologies Group (SHTG)	Dxcover brain cancer liquid biopsy test for early brain cancer detection in primary care
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Naldemedine (opioid-induced constipation) - Benefit assessment according to §35a Social Code Book V]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Romosozumab (osteoporosis) - Addendum to Commission A20-24]
2020	National Committee for Technology Incorporation (CONITEC)	[Dolutegravir for the treatment of pregnant women living with HIV]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ponatinib (chronic myeloid leukaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2020	National Committee for Technology Incorporation (CONITEC)	[Baricitinib (Olumiant) for patients with moderate to severe active rheumatoid arthritis]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ponatinib (Philadelphia chromosome positive acute lymphoblastic leukaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2020	Agency for Healthcare Research and Quality (AHRQ)	Care interventions for people living with dementia and their caregivers
2020	NIHR Health Technology Assessment programme	A systematic review of psychological interventions to improve motivation for self-management in people with type 1 and type 2 diabetes
2020	National Committee for Technology Incorporation (CONITEC)	[Mirabegron for the treatment of storage dysfunction in patients with neurogenic bladder]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Talazoparib (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2020	NIHR Health Services and Delivery Research programme	Using co-production to improve patient carer and staff experiences in health care organizations: a multi-centre, mixed methods evaluation in inpatient stroke units (CREATE)
2020	National Committee for Technology Incorporation (CONITEC)	[Antimuscarinics (oxybutynin, tolterodine, solifenacin and darifenacin) for the treatment of storage dysfunction in patients with neurogenic bladder]
2020	Agency for Healthcare Research and Quality (AHRQ)	Characteristics of existing asthma self-management education packages